PD44-05 CONTEMPORARY NATIONAL TRENDS OF PROSTATE CANCER SCREENING AMONG PRIVATELY INSURED PATIENTS IN THE UNITED STATES

Abstract

You have accessJournal of UrologyProstate Cancer: Detection and Screening IV1 Apr 2015PD44-05 CONTEMPORARY NATIONAL TRENDS OF PROSTATE CANCER SCREENING AMONG PRIVATELY INSURED PATIENTS IN THE UNITED STATES Simon Kim, R. Jeffrey Karnes, Cary Gross, Holly Van Houten, Robert Abouassaly, and Nilay Shah Simon KimSimon Kim More articles by this author , R. Jeffrey KarnesR. Jeffrey Karnes More articles by this author , Cary GrossCary Gross More articles by this author , Holly Van HoutenHolly Van Houten More articles by this author , Robert AbouassalyRobert Abouassaly More articles by this author , and Nilay ShahNilay Shah More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.2551AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES With the recent changes to clinical practice guidelines for prostate cancer (PC) screening, little is known the degree to which PC screening with prostate-specific antigen (PSA) testing has changed, if at all. Therefore, we used a large private health insurance database to determine the national trends of PSA screening and investigate which patient characteristics associated with PSA testing. METHODS Using a large private health insurance claims database Optum Labs Data Warehouse), we identified males age 40-80 years who underwent PC screening from 2008 to 2013. The primary outcome was use of PSA testing among a privately insured population-based cohort. Demographic covariates included age, census region, race, education level and household income range. The Charlson/Deyo comorbidity index was calculated to assess comorbidity burden. Rates were calculated based on member-years and reported per 1,000 member-years. RESULTS Among the 11.6 million eligible enrollees, we identified 2.9 million (25%) men who underwent PSA screening from 2008 to 2013. The majority of the over 800,000 enrollees screened each year were white males, age 50-59 years residing in the Southern census region. The rate of men undergoing PSA screening remained stable from 190.4 per 1,000 member-years in 2008 to 196.4 in 2013 (p=0.66). Among enrollees aged 50 to 74 years old, PSA screening rates were relatively stable. However, enrollees who were > 75 years old had a marked decrease in PSA screening from 201.5 to 124.1 per 1,000 member-years from 2008 to 2013 (p=0.04). PSA screening rates did not vary by racial groups over time. CONCLUSIONS In this population-based cohort of privately insured men, we found little effect of PSA screening from changes to clinical practice guidelines overall except for men who were advanced age. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e899 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Simon Kim More articles by this author R. Jeffrey Karnes More articles by this author Cary Gross More articles by this author Holly Van Houten More articles by this author Robert Abouassaly More articles by this author Nilay Shah More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...